Eli Lilly

News

Lilly, Novo Nordisk sued over GLP-1 drug safety

A lawsuit has been filed in the US claiming that Novo Nordisk and Eli Lilly failed to warn of severe gastrointestinal side effects that can be caused by their incretin mim

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Lilly bulks up in obesity with $1.93bn Versanis buy

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1

News

Sensorion files to start trials of deafness gene therapy

French biotech Sensorion has filed its first regulatory application to start human testing of OTOF-GT, a gene therapy for one of the most common forms of congenital deafne

News

Lilly ends ADA on a high as obesity triple data pops

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru

Lilly, Novo Nordisk sued over GLP-1 drug safety

Jardiance cleared in EU for CKD, challenging Forxiga

Donanemab data an “important advance” in Alzheimer’s

Lilly bulks up in obesity with $1.93bn Versanis buy

Sensorion files to start trials of deafness gene therapy

Lilly ends ADA on a high as obesity triple data pops

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks